We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tiziana Life Sciences Plc | LSE:TILS | London | Ordinary Share | GB00BKWNZY55 | ORD 3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.50 | 45.00 | 60.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
20/1/2021 09:39 | please do not say "golden tickets" - people used to use that phrase with Quindell lol | yidarmytom | |
20/1/2021 09:33 | Mms scrabbling for shares don't sell them golden tickets folks. | mark0419 | |
20/1/2021 09:28 | Stemprinter? All very quiet on this any date yet for listing? | ayl30 | |
20/1/2021 09:17 | last chance to buy stamp duty free, roll up roll up folks!! | yidarmytom | |
20/1/2021 09:15 | Who we going to have put the balloons and bunting up for our last day on AIM.Shall we get that tool andymunchkin to put them up. I'll do the buffet.....pmsl | mark0419 | |
20/1/2021 09:12 | Fund will buy now | nw99 | |
20/1/2021 09:10 | Among the positive results that patients reported, the most common observation was that the treatment resulted in rapid improvement in smell sensation, which is frequently lost in COVID-19-infected patients (a condition known as anosmia)," said HCW analyst Raghuram Selvaraju.He also hailed the appointment as chief medical officer of Dr Neil Graham, an industry veteran with experience of successfully developing blockbuster monoclonal antibody products.He flagged as a potential "game-changer" the ability to deliver antibody immuno-therapeutics both orally and nasally, an approach being pioneered with Foralumab | mark0419 | |
20/1/2021 09:06 | It's coming | markstevenkirby80 | |
20/1/2021 08:58 | Needs repeating........The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients. | mark0419 | |
20/1/2021 07:40 | Today's RNS mentions ... (not sure this would have been reiterated unless some good news was forthcoming) ...The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients. | jpuff | |
19/1/2021 21:26 | Closed 5% up stateside this evening. Sweet dreams, JP | jpuff | |
19/1/2021 21:13 | So HC Wainwright reiterates a 'Buy' rating with a top 100 analyst...it sure is providing the impetus today...but 'Mr Analyst', I see that you state the appointment of Dr Graham clearly signals Tiziana's intent to build a world class organisation but have you thought about the wider implications of Regeneron losing such a prolific industry veteran or have they... Seems strange to leave a $50B company in the midst of such undeniable potential unless 'Bigger Games' are being played unbeknown to the 'Common Investor'...agendas, agendas hey! | rebelwithacause1 | |
19/1/2021 19:44 | With comments like that Imp, I don't think you actually read my comments...but if its any consolation, you're wrong. | rebelwithacause1 | |
19/1/2021 19:38 | You from the start have sown doubt and mistrust, trying to destroy value and confidence, About right aye Reb, am I wrong | impala391 | |
19/1/2021 19:34 | No I sussed you from the start, just got confirmation as time went by. | impala391 | |
19/1/2021 19:31 | Has the 'Mystery' disappeared now Imp - hehe! | rebelwithacause1 | |
19/1/2021 19:25 | Reb your a bit transparent now ! | impala391 | |
19/1/2021 19:11 | Why should it?...But I see the resemblance from your comments. | rebelwithacause1 | |
19/1/2021 19:06 | REB, Does it make you insecure that im a lady.... | fandagle | |
19/1/2021 18:34 | Hehe - I cannot agree more Imp, a 'Scum Nation'!...but unfortunately 'Direction of Travel' continues to be dictated by them. Lets hope it isn't a dire mistake by GC to be listed in the US first before main market and traction had been achieved... | rebelwithacause1 | |
19/1/2021 18:19 | US their just useless, about as much use as a fart in a funderstorm. | impala391 | |
19/1/2021 17:39 | How very interesting Fan that you're female! Tom, the trial cohort is too small for Dr Weiner to assume with any real confidence that there are no side effects buddy...so just be very careful especially with the continuous demise in the US... | rebelwithacause1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions